Cancer.Net Associate Editor: Sarcoma
Hofstra-Northwell School of Medicine & Cold Spring Harbor Laboratory
Dr. Robert Maki is Professor of Medicine, at Hofstra-Northwell and Cold Spring Harbor Laboratory, just east of New York City. He has published over 140 peer-reviewed articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. He treats adults and adolescents with sarcomas, which are connective tissue cancers of bone, cartilage, muscle, fat and other soft tissue such as GIST, leiomyosarcoma, angiosarcoma, osteosarcoma, and desmoid tumors.
Dr. Maki earned his medical and doctorate degree at Cornell University Medical College in New York City. He completed his residency at Brigham and Women's Hospital in Boston before completing his medical oncology fellowship at Dana-Farber, also in Boston. He is a fellow of the American College of Physicians.
One of the recognized thought leaders regarding sarcoma medical oncology, Dr. Maki has developed efforts in collaborative sarcoma research, both in the laboratory and in the clinic. Dr. Maki has broad interests in the biology of sarcomas of soft tissue and bone, as well as clinical trials and new drug development for this diverse group of diseases, and he has participated extensively in national and international studies in sarcoma. He is leading both sarcoma medicine and new drug development at Monter Cancer Center, associated with Northwell Health. He is also involved in moving new biological ideas from Cold Spring Harbor Laboratory to fruition in the clinic.
Disclosure: In the past two years, Dr. Maki has served as a consultant/advisor to Arcus, Bayer, Eisai, Gem Pharmaceuticals, Immune Design, Lilly, Pfizer CURES, and Tracon; as of 2017, he and/or his institution receives research funding from Sarcoma Alliance for Research through Collaboration (SARC), Immune Design, Regeneron and Tracon Pharmaceuticals.
Last updated: Mar 2017